Raymond U Osarogiagbon

List of Publications by Year
in descending order

82 papers	2,207 citations	201674 27 h-index	265206 42 g-index
83 all docs	83 docs citations	83 times ranked	1570 citing authors

#	Article	IF	Citations
1	Prospective Comparative Effectiveness Trial of Multidisciplinary Lung Cancer Care Within a Community-Based Health Care System. JCO Oncology Practice, 2023, 19, e15-e24.	2.9	4
2	The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. Chest, 2022, 162, 242-255.	0.8	4
3	eSyM: An Electronic Health Recordâ€“Integrated Patient-Reported Outcomesâ€“Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Informatics, 2022, 6, e2100137.	2.1	19
4	Ruralâ€“Urban Disparities in Cancer Outcomes: Opportunities for Future Research. Journal of the National Cancer Institute, 2022, 114, 940-952.	6.3	46
5	Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. Journal of Clinical Oncology, 2022, 40, 2094-2105.	1.6	32
6	Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncology, 2022, 8, 717.	7.1	32
7	Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. Trials, 2022, 23, .	1.6	9
8	â€œWhen Offered to Participateâ€: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. Journal of the National Cancer Institute, 2021, 113, 244-257.	6.3	116
9	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. Chest, 2021, 159, 1630-1641.	0.8	10
10	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCOâ€“Friends of Cancer Research Prior Therapies Work Group. Clinical Cancer Research, 2021, 27, 2408-2415.	7.0	14
11	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 66-78.	3.8	23
12	Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis. JTO Clinical and Research Reports, 2021, 2, 100161.	1.1	2
13	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. Journal of Clinical Oncology, 2021, 39, 1339-1348.	1.6	62
14	Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. Journal of Thoracic Oncology, 2021, 16, 630-642.	1.1	15
15	Barriers to web-based symptom management systems (web-SyMS).. Journal of Clinical Oncology, 2021, 39, 6545-6545.	1.6	0
16	Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes. Journal of Thoracic Oncology, 2021, 16, 774-783.	1.1	10
17	The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events. Lung Cancer, 2021, 155, 191-192.	2.0	0
18	Response to: â€œLymph Node Dissection for Nonâ€“Small-Cell Lung Cancer at Whose Discretion?â€: Journal of Thoracic Oncology, 2021, 16, e36-e37.	1.1	0

#	Article	IF	Citations
19	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 2021, 16, 897-901.	1.1	8
20	Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System. JTO Clinical and Research Reports, 2021, 2, 100203.	1.1	6
21	Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States. Journal of Thoracic Oncology, 2021, 16, 1663-1671.	1.1	7
22	â€œAll boats will riseâ€: Physiciansâ€™ perspectives on multidisciplinary lung cancer care in a community-based hospital setting. Supportive Care in Cancer, 2020, 28, 1765-1773.	2.2	6
23	County-Level Variations in Receipt of Surgery for Early-Stage Non-small Cell LungÂCancer in the United States. Chest, 2020, 157, 212-222.	0.8	24
24	Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization. Journal of Thoracic Oncology, 2020, 15, 371-382.	1.1	39
25	Volume-Based Care Regionalization: Pitfalls and Challenges. Journal of Clinical Oncology, 2020, 38, 3465-3467.	1.6	7
26	Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2020, 15, e185-e186.	1.1	1
27	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectrum, 2020, 4, pkaa034.	2.9	59
28	Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer. Chest, 2020, 158, 787-796.	0.8	19
29	Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 1670-1681.	1.1	32
30	Invasive mediastinal staging for resected nonâ€“small cell lung cancer in a population-based cohort. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1220-1229.e2.	0.8	29
31	Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort. Annals of Thoracic Surgery, 2019, 107, 1487-1493.	1.3	8
32	Early-Stage NSCLC: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 968-978.	1.1	35
33	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	1.1	49
34	Progress in the Management of Early-Stage Nonâ€“Small Cell Lung Cancer in 2017. Journal of Thoracic Oncology, 2018, 13, 767-778.	1.1	24
35	Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 228-234.	1.3	16
36	Association of Pathologic Nodal Staging Quality With Survival Among Patients With Nonâ€“Small Cell Lung Cancer After Resection With Curative Intent. JAMA Oncology, 2018, 4, 80.	7.1	94

#	Article	IF	Citations
37	Reducing Bottlenecks to Improve the Efficiency of the Lung Cancer Care Delivery Process: A Process Engineering Modeling Approach to Patient-Centered Care. Journal of Medical Systems, 2018, 42, 16.	3.6	5
38	Achieving Better Quality of Lung Cancer Care. , 2018, , 167-182.		2
39	Pragmatic trial of a multidisciplinary lung cancer care model in a community healthcare setting: study design, implementation evaluation, and baseline clinical results. Translational Lung Cancer Research, 2018, 7, 88-102.	2.8	14
40	â€œLike heart valve clinic, it probably saves lives, butâ€¦ Who has time for that?â€•The challenge of disseminating multidisciplinary cancer care in the <scp>U</scp>nited <scp>S</scp>tates. Cancer, 2018, 124, 3634-3637.	4.1	10
41	Making the Evidentiary Case for Universal Multidisciplinary Thoracic Oncologic Care. Clinical Lung Cancer, 2018, 19, 294-300.	2.6	17
42	Pragmatic study of a lymph node (LN) collection kit for non-small cell lung cancer (NSCLC) resection.. Journal of Clinical Oncology, 2018, 36, 8502-8502.	1.6	1
43	Evolution in the Surgical Care of Patients With Nonâ€“Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 91-101.	0.6	12
44	Survival impact of postoperative therapy modalities according to margin status in nonâ€“small cell lung cancer patients in the United States. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 661-672.e10.	0.8	31
45	Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria. Annals of Thoracic Surgery, 2017, 103, 1557-1565.	1.3	31
46	Risk-Adjusted Margin Positivity Rate as a Surgical Quality Metric for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2017, 104, 1161-1170.	1.3	15
47	Management of screening-detected stage I lung cancer. Journal of Thoracic Disease, 2016, 8, E1416-E1419.	1.4	4
48	Improving post-resection risk stratification in non-small cell lung cancer: â€˜wit, whither wander you?â€™. Journal of Thoracic Disease, 2016, 8, 2315-2318.	1.4	0
49	Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. Translational Lung Cancer Research, 2016, 5, 258-264.	2.8	11
50	Strategic approach to minimally invasive mediastinal nodal stagingâ€”a brave new world?. Lancet Respiratory Medicine,the, 2016, 4, 926-927.	10.7	2
51	Overcoming the Implementation Gap in Multidisciplinary Oncology Care Programs. Journal of Oncology Practice, 2016, 12, 888-891.	2.5	11
52	Deploying Team Science Principles to Optimize Interdisciplinary Lung Cancer Care Delivery: Avoiding the Long and Winding Road to Optimal Care. Journal of Oncology Practice, 2016, 12, 983-991.	2.5	24
53	Reply. Annals of Thoracic Surgery, 2016, 101, 1628-1629.	1.3	0
54	Comment on the Proposals for the Revision of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1612-1614.	1.1	24

#	Article	IF	Citations
55	Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance). Annals of Thoracic Surgery, 2016, 102, 363-369.	1.3	55
56	Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2016, 102, 448-453.	1.3	59
57	Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Nonâ€“Small Cell Lung Cancer in the U.S. National Cancer Data Base. Journal of Thoracic Oncology, 2016, 11, e5-e16.	1.1	55
58	Physiciansâ€™ perspectives on multidisciplinary (MD) lung cancer care in a community-based hospital setting.. Journal of Clinical Oncology, 2016, 34, 6544-6544.	1.6	1
59	Reply. Annals of Thoracic Surgery, 2015, 100, 768-769.	1.3	1
60	Audit of Lymphadenectomy in Lung Cancer Resections Using a Specimen Collection Kit and Checklist. Annals of Thoracic Surgery, 2015, 99, 421-427.	1.3	29
61	Preoperative Evaluation of Lung Cancer in a Community Health Care Setting. Annals of Thoracic Surgery, 2015, 100, 394-400.	1.3	32
62	Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs. Translational Lung Cancer Research, 2015, 4, 448-55.	2.8	17
63	'One-stop shop': lung cancer patients' and caregivers' perceptions of multidisciplinary care in a community healthcare setting. Translational Lung Cancer Research, 2015, 4, 456-64.	2.8	37
64	Improving lung cancer outcomes by improving the quality of surgical care. Translational Lung Cancer Research, 2015, 4, 424-31.	2.8	16
65	Measuring improvement in populations: implementing and evaluating successful change in lung cancer care. Translational Lung Cancer Research, 2015, 4, 373-84.	2.8	1
66	Improving the pathologic evaluation of lung cancer resection specimens. Translational Lung Cancer Research, 2015, 4, 432-7.	2.8	12
67	Computer modeling of lung cancer diagnosis-to-treatment process. Translational Lung Cancer Research, 2015, 4, 404-14.	2.8	8
68	Size and histologic characteristics of lymph node material retrieved from tissue discarded after routine pathologic examination of lung cancer resection specimens. Annals of Diagnostic Pathology, 2014, 18, 136-139.	1.3	8
69	Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Nonâ€“Small Cell Lung Cancer. Annals of Thoracic Surgery, 2014, 97, 385-393.	1.3	130
70	The impact of a novel lung gross dissection protocol on intrapulmonary lymph node retrieval from lung cancer resection specimens. Annals of Diagnostic Pathology, 2014, 18, 220-226.	1.3	25
71	Nonexamination of Lymph Nodes and Survival After Resection of Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2013, 96, 1178-1189.	1.3	85
72	Dual Intervention to Improve Pathologic Staging of Resectable Lung Cancer. Annals of Thoracic Surgery, 2013, 96, 1975-1981.	1.3	15

#	Article	IF	Citations
73	Towards optimal pathologic staging of resectable non-small cell lung cancer. Translational Lung Cancer Research, 2013, 2, 364-71.	2.8	17
74	Incomplete Intrapulmonary Lymph Node Retrieval After Routine Pathologic Examination of Resected Lung Cancer. Journal of Clinical Oncology, 2012, 30, 2823-2828.	1.6	102
75	Objective Review of Mediastinal Lymph Node Examination in a Lung Cancer Resection Cohort. Journal of Thoracic Oncology, 2012, 7, 390-396.	1.1	73
76	Use of a Surgical Specimen-Collection Kit to Improve Mediastinal Lymph-Node Examination of Resectable Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1276-1282.	1.1	44
77	Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Nonâ€“Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database. Journal of Thoracic Oncology, 2012, 7, 1798-1806.	1.1	110
78	Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. Journal of Thoracic Disease, 2012, 4, 214-6.	1.4	18
79	Pathologic Lymph Node Staging Practice and Stage-Predicted Survival After Resection of Lung Cancer. Annals of Thoracic Surgery, 2011, 91, 1486-1492.	1.3	39
80	Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Cancer, 2011, 117, 134-142.	4.1	58
81	Causes and Consequences of Deviation from Multidisciplinary Care in Thoracic Oncology. Journal of Thoracic Oncology, 2011, 6, 510-516.	1.1	44
82	Outcome of Surgical Resection for Pathologic N0 and Nx Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 191-196.	1.1	41